| 1 |
34500449 | Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis. | 2022 |
3 |
| 2 |
35114188 | Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration. | 2022 Mar |
4 |
| 3 |
35361724 | Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. | 2022 Apr |
1 |
| 4 |
32940725 | Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia. | 2021 Feb |
1 |
| 5 |
33063127 | Correction to: Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia. | 2021 Jan |
1 |
| 6 |
33475252 | Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy. | 2021 Jun |
2 |
| 7 |
33853432 | Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review. | 2021 Apr |
2 |
| 8 |
34021853 | Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation. | 2021 Nov |
4 |
| 9 |
34128578 | Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease. | 2021 Jul |
3 |
| 10 |
34497233 | [Diagnosis and management of pure red cell aplasia]. | 2021 |
1 |
| 11 |
34754441 | Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia. | 2021 Nov |
1 |
| 12 |
34756787 | A Prospective, Self-Controlled Pilot Study of the Efficacy of Roxadustat for Erythropoietin Hyporesponsiveness in Patients Requiring Chronic Ambulatory Peritoneal Dialysis. | 2021 Oct 29 |
3 |
| 13 |
32309288 | Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. | 2020 Mar |
3 |
| 14 |
32380083 | The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia. | 2020 Jul |
2 |
| 15 |
32603526 | Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. | 2020 Nov |
1 |
| 16 |
32856389 | Resolution of epoetin-induced pure red cell aplasia, successful re-challenge with roxadustat. | 2020 Dec |
1 |
| 17 |
33344604 | Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report. | 2020 Dec 6 |
1 |
| 18 |
31340116 | Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. | 2019 Sep 12 |
1 |
| 19 |
29254377 | Roxadustat in the treatment of anaemia in chronic kidney disease. | 2018 Jan |
1 |
| 20 |
26846333 | Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. | 2016 Jun |
1 |
| 21 |
26238121 | Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. | 2015 Oct |
1 |